Terasaki Institute Develops Organ-on-Chip Platform to Test Cancer Vaccines in Aging Populations
Key Insights
Researchers at the Terasaki Institute have developed a lymph node-inspired organ-on-chip platform that models age-dependent immune responses for testing cancer (search) vaccine efficacy in older adults.
The platform revealed that young antigen-presenting cells (search) showed significantly stronger peptide presentation compared to older cells, leading to enhanced T cell (search) activation and cytotoxicity against cancer (search) cells.
This technology addresses a critical gap in vaccine development, as immunosenescence (search) significantly reduces cancer (search) vaccine effectiveness in older populations who face the highest cancer risk.
Dr. Vadim Jucaud's laboratory at the Terasaki Institute for Biomedical Innovation (search) has developed a groundbreaking organ-on-chip platform that models age-dependent immune responses, providing researchers with a more accurate method for evaluating cancer (search) vaccine performance in older adults. This innovation addresses a significant gap in preclinical testing, as older populations are most affected by cancer yet often overlooked in traditional vaccine development pipelines.
Addressing Immunosenescence in Cancer Vaccine Development
Immunosenescence (search), the natural decline of the immune system with age, significantly reduces the effectiveness of cancer vaccines (search). Despite its clinical importance, age-related immune decline is seldom incorporated into vaccine development processes. Current 2D culture systems fail to capture the complex age-specific immune responses, limiting their predictive value for clinical translation.
The research team developed a lymph node paracortex-inspired organ-on-chip platform that models key steps in cancer (search) vaccine immune responses. These steps include antigen presentation, antigen-specific T cell (search) activation, and downstream tumor-specific cytotoxicity. By comparing immune responses from young and older lymphocytes, the platform captures functional differences that naturally emerge with age.
Platform Demonstrates Age-Related Immune Differences
Using this innovative platform, the team demonstrated that young antigen-presenting cells (search) displayed significantly stronger peptide presentation compared to old cells. This increased activity led to higher activation of antigen-specific T cells and enhanced cytotoxicity against cancer (search) cells. Notably, these age-dependent differences were detectable only with the lymph node on-a-chip system, underscoring its ability to reveal biologically relevant immune variations that traditional 2D cultures cannot detect.
"This work introduces our lymph node on-a-chip platform for cancer (search) vaccine testing," said Dr. Vadim Jucaud, Principal Investigator and Assistant Professor at the Terasaki Institute. "Unlike traditional 2D models, this advanced system replicates age-related immune responses, which is critical because older adults face the highest cancer risk and often have diminished immunity. By accurately modeling these conditions in vitro, our platform enables more reliable insights into cancer vaccine performance, therefore accelerating development and improving outcomes."
Implications for Future Immunotherapy Development
By more accurately reflecting the biology of aging, this novel platform offers a valuable tool for understanding how immunosenescence (search) influences cancer (search) vaccine efficacy. The technology may help guide the development of next-generation immunotherapies designed to meet the needs of older patients, ensuring that emerging cancer treatments support those who depend on them most.
The platform's ability to capture age-specific immune responses represents a significant advancement in preclinical testing methodologies, potentially leading to more effective cancer vaccines (search) for the aging population most vulnerable to cancer (search).